Kirit Singh
@kiritsingh.bsky.social
Immuno-engineering at Duke Brain Tumor Center & Adaptin Bio | MD, PhD @QMULBartsTheLon, @DukeUBME | 🇬🇧 in 🇺🇸
Reposted by Kirit Singh
In glioma, T cell immunotherapies are limited by the quantity of available T cells.
@kiritsingh.bsky.social & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7.
Full report buff.ly/gslmMgl
@kiritsingh.bsky.social & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7.
Full report buff.ly/gslmMgl
June 25, 2025 at 1:20 PM
In glioma, T cell immunotherapies are limited by the quantity of available T cells.
@kiritsingh.bsky.social & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7.
Full report buff.ly/gslmMgl
@kiritsingh.bsky.social & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7.
Full report buff.ly/gslmMgl
Reposted by Kirit Singh
LOOK WHAT MY FRIEND @kiritsingh.bsky.social SPOTTED IN NORTH CAROLINA YESTERDAY. WHAT! #GTFC who is this and how can we be friends?
January 27, 2025 at 8:28 PM
LOOK WHAT MY FRIEND @kiritsingh.bsky.social SPOTTED IN NORTH CAROLINA YESTERDAY. WHAT! #GTFC who is this and how can we be friends?